Acetylcysteine

Generic Name: Acetylcysteine

Brand Names: Acetadote

Drug Type: Small Molecule

Chemical Formula: C_₅H_₉NO_₃S

CAS Number: 616-91-1

Unique Ingredient Identifier: WYQ7N0BPYC

Background: Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.

Acetylcysteine was granted FDA approval on 14 September 1963.

Indication: Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose.

Associated Conditions: Acetaminophen Overdose, Chronic Rhinitis, Corneal Diseases, Corneal ulceration, Crusting Rhinitis, Keratopathy, Rhinitis, Sinusitis, Vasomotor Rhinitis, Acute Rhinitis, Subacute Rhinitis

Associated Therapies: Airway secretion clearance therapy

Clinical Trials

Exploratory Efficacy of N-Acetylcysteine in Patients With History of COVID-19

Phase 2

Active, not recruiting

Conditions: COVID-19

Interventions: Drug: N-Acetylcysteine
Drug: Placebo

First Posted Date: 2023-02-21

Last Posted Date: 2023-02-21

Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Target Recruit Count: 80

Registration Number: NCT05736887

Locations: 🇮🇹
Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Roma, Italy

N-acetylcysteine (NAC) for the Treatment of Acute Exacerbation of COPD

Phase 3

Recruiting

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Placebo
Drug: N-acetylcysteine

First Posted Date: 2023-01-31

Last Posted Date: 2023-11-18

Lead Sponsor: Queen Mary Hospital, Hong Kong

Target Recruit Count: 80

Registration Number: NCT05706402

Locations: 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong

N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia

Phase 4

Terminated

Conditions: Lymphoblastic Leukemia, Acute, Childhood

Interventions: Drug: Placebo
Drug: N-Acetylcysteine

First Posted Date: 2022-11-09

Last Posted Date: 2022-11-09

Lead Sponsor: Teny Tjitra Sari

Target Recruit Count: 16

Registration Number: NCT05611086

Locations: 🇮🇩
Dr Cipto Mangunkusumo National Hospital, Jakarta Pusat, DKI Jakarta, Indonesia

Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, N-Acetylcysteine)

Early Phase 1

Recruiting

Conditions: Cocaine Use Disorder
Opioid Use Disorder

Interventions: Drug: n-acetylcysteine
Drug: Hydromorphone
Drug: Placebo n-acetylcystine
Drug: Placebo hydromorphone

First Posted Date: 2022-11-09

Last Posted Date: 2024-12-12

Lead Sponsor: William Stoops

Target Recruit Count: 24

Registration Number: NCT05610072

Locations: 🇺🇸
University of Kentucky Laboratory of Human Behavioral Pharmacology, Lexington, Kentucky, United States
🇺🇸
University of Kentucky Department of Behavioral Science, Lexington, Kentucky, United States

Oral N-acetylcysteine for Retinitis Pigmentosa

Phase 3

Recruiting

Conditions: Retinitis Pigmentosa

Interventions: Drug: Placebo
Drug: N-acetylcysteine

First Posted Date: 2022-09-13

Last Posted Date: 2024-12-13

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 438

Registration Number: NCT05537220

Locations: 🇺🇸
University of California - Davis, Department of Ophthalmology & Vision Science, Davis, California, United States
🇺🇸
Stanford University, Byers Eye Institute, Stanford, California, United States
🇺🇸
Vitreo Retinal Associates, Gainesville, Florida, United States

and more 29 locations

A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers

Phase 2

Not yet recruiting

Conditions: Huntington Disease

Interventions: Drug: Placebo
Drug: NAC

First Posted Date: 2022-08-19

Last Posted Date: 2022-08-24

Lead Sponsor: Western Sydney Local Health District

Target Recruit Count: 160

Registration Number: NCT05509153

Locations: 🇦🇺
The Royal Melbourne Hospital, Parkville, Victoria, Australia
🇦🇺
Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺
The University of Queensland, Herston, Queensland, Australia

and more 2 locations

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label

Phase 2

Conditions: Autism Spectrum Disorder

Interventions: Drug: N-acetylcysteine

First Posted Date: 2022-08-10

Last Posted Date: 2024-08-26

Lead Sponsor: Stanford University

Target Recruit Count: 48

Registration Number: NCT05494398

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy

Phase 2

Recruiting

Conditions: Drug Resistant Epilepsy

Interventions: Drug: N-acetyl cysteine
Drug: Placebo
Drug: NAc

First Posted Date: 2022-08-03

Last Posted Date: 2023-05-23

Lead Sponsor: Tanta University

Target Recruit Count: 45

Registration Number: NCT05485558

Locations: 🇪🇬
Tanta University, Tanta, Egypt

Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32)

Not Applicable

Conditions: Alcoholic Hepatitis

Interventions: Drug: N-acetylcysteine

First Posted Date: 2022-03-24

Last Posted Date: 2022-03-24

Lead Sponsor: Bioaraba Health Research Institute

Target Recruit Count: 390

Registration Number: NCT05294744

Locations: 🇪🇸
Ana Belén Fernández Laso, Vitoria-Gasteiz, Álava, Spain

Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease

Phase 1

Conditions: COVID-19 Pneumonia
COVID-19
Ventilator Associated Pneumonia
COVID-19 Acute Respiratory Distress Syndrome

Interventions: Drug: Bromelains
Drug: Acetylcysteine

First Posted Date: 2022-02-28

Last Posted Date: 2022-02-28

Lead Sponsor: Mucpharm Pty Ltd

Target Recruit Count: 30

Registration Number: NCT05258682

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy